EGFR and lung carcinoma: Outside of EGFR TKIs, the bi-specific EGFR antibody amivantamab-vmjw has shown some preclinical activity against multiple EGFR mutated lung cancer models and was also approved for use in advanced EGFR exon 20 insertion mutated lung cancer [9].